Virus-HIV
10
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV
Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
Becoming HIV-Exposed, Uninfected Children Born to HIV-Positive Mothers Followed at Bichat Claude Bernard Hospital
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
Life Experience of People Aged 60 and Over Living with HIV
Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
HIV A6 Genome In ART Unsuccessful Patients On DOR
Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP
QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient
Coronary Artery Disease (CAD) in Suppressed HIV-infected